Matt Hill, Ph.D., is founder and CEO of Elegen Corp., a privately-held company based in the San Francisco Bay Area, committed to revolutionizing genetic medicine and synthetic biology workflows with an innovative cell-free DNA manufacturing technology. Armed with a vision to eliminate the DNA bottleneck at the core of all synthetic biology applications, Hill founded Elegen in 2017 to innovate the DNA build process. Under his direction, the company launched ENFINIA™ DNA in 2023 with industry-leading length, complexity, accuracy, and speed to accelerate discovery for healthcare and pharma as well as agbio and synbio industries. Hill previously served as VP of R&D at Natera, where he co-invented their core technology and led the commercialization of five precision molecular diagnostics products, enabling their successful 2015 IPO. An accomplished scientist, engineer, and entrepreneur with a Ph.D. from Stanford, he is driven to create lasting positive impacts on the world.

‍